Fakhoury Ranni Emad Reports 5.02% Stake in SenesTech
Fakhoury Ranni Emad has disclosed a 5.02% ownership in SenesTech, Inc., signaling potential strategic interests in the agriculture chemicals sector.
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Richard B. Handler, CEO of Jefferies Financial Group, reports stock transactions reflecting estate planning, as detailed in a recent SEC filing.
Brophy Michael Burkes sells 3,084 shares of Natera stock
Brophy Michael Burkes, CFO of Natera, Inc., sold 3,084 shares of common stock, signaling adjustments in executive holdings and compliance in the medical sector.
JANA Partners cuts stake in Alkami Technology below 5%
JANA Partners Management, LP reduces its stake in Alkami Technology, Inc., allowing for flexible discussions with the board. Details revealed in SEC filing.
Powell Anderson Capital Partners Amends Stake in Franklin Street
Powell Anderson Capital Partners LLC amends its Schedule 13D, revealing an 8.0% stake in Franklin Street Properties Corp, enhancing its influence in the REIT sector.
Glenbrook Capital Management Boosts Stake in SenesTech
Glenbrook Capital Management increases its stake in SenesTech, acquiring 30,000 shares, signaling confidence in the agricultural chemicals sector.
Glenbrook Capital Management Increases Stake in SenesTech
Glenbrook Capital Management now holds over 40% of SenesTech, signaling potential strategic shifts in the agricultural chemicals sector.
MediaAlpha updates ownership stake in Schedule 13D/A filing
MediaAlpha, Inc. updates its Schedule 13D/A, revealing a 35.1% ownership stake by White Mountains Insurance Group and WM Hinson.
SB Global Advisers Amends Schedule 13D for VTEX Stake
SB Global Advisers Ltd has increased its stake in VTEX to 42.9%, as revealed in a recent SEC filing, impacting the prepackaged software industry.
Chuang Hao-Yuan acquires 5,000 shares in Belite Bio, Inc.
Chuang Hao-Yuan has acquired 5,000 shares in Belite Bio, Inc. as part of a stock award, signaling executive commitment in the pharmaceutical sector.
OS Therapies grants stock options to Chief Medical Officer
OS Therapies Inc grants stock options to CMO Robert Petit, highlighting its commitment to key personnel in the competitive pharmaceutical industry.
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Lin Yu-Hsin, CEO of Belite Bio, vests 5,000 shares after meeting performance criteria, highlighting executive compensation trends in the pharmaceutical sector.
Chen Wan-Shan Reports Share Transaction for Belite Bio
Chen Wan-Shan disclosed a transaction involving 13,796 shares of Belite Bio, reflecting active engagement in the pharmaceutical sector.
Clem Kerry M Reports 300,000 Stock Options in SEC Filing
Clem Kerry M, Chief Commercial Officer of OS Therapies, reports 300,000 stock options in SEC filing, highlighting executive incentives and growth potential.
OS Therapies grants stock options to director Craig Eagle
OS Therapies Inc grants 300,000 stock options to director Craig Eagle, signaling commitment to leadership incentives and aligning interests in the pharmaceutical industry.
OS Therapies grants stock options to CFO Francis Knuettel II
OS Therapies Inc has granted stock options to CFO Francis Knuettel II, highlighting its strategy to incentivize key executives in the pharmaceutical industry.
OS Therapies grants stock options to board member Jarry Olivier
OS Therapies Inc has granted stock options to board member Jarry Olivier Roger, reflecting its strategy to incentivize leadership in the competitive pharmaceutical industry.
OS Therapies CEO Romness Receives Major Stock Option Grant
OS Therapies Inc CEO Paul A. Romness has been granted stock options for 900,000 shares, reflecting the company's commitment to incentivizing leadership.
OS Therapies grants stock options to director Avril McKean-Dieser
Avril McKean-Dieser receives stock options from OS Therapies, highlighting executive compensation strategies in the pharmaceutical sector.
Ciccio John Reports Stock Options and Holdings in OS Therapies
Ciccio John discloses stock options and shareholdings in OS Therapies Inc, reflecting his commitment to the company and the pharmaceutical sector.